(Q38293774)

1 September 2017

1 reference

title

Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

1 September 2017

main subject

0 references

author name string

Jon Florholmen

series ordinal

1

1 reference

1 September 2017

publication date

1 January 2015

1 reference

Scandinavian Journal of Gastroenterology

1 September 2017

published in

1 reference

1 September 2017

volume

50

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

43-52

1 reference

The burden of inflammatory bowel disease in Europe

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Genetics and pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

New biologic therapeutics for ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing in Crohn's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Biological therapies for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Intestinal mucosal barrier function in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing in inflammatory bowel diseases: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Deep remission in inflammatory bowel disease: looking beyond symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

NOD-like receptors in intestinal homeostasis and epithelial tissue repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Matrix metalloproteinases in inflammatory bowel disease: boon or a bane?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Insights into IBD Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

TNF and MAP kinase signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Signaling pathways associated with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Pleiotropic functions of TNF-α in the regulation of the intestinal epithelial response to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

TNF-α converting enzyme-mediated ErbB4 transactivation by TNF promotes colonic epithelial cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing and deep remission: what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing as an index of colitis activity: Back to histological healing for future indices

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Histologic remission: the ultimate therapeutic goal in ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Importance of mucosal healing in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

How Rapidly Should Remission Be Achieved?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn?s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Future directions in inflammatory bowel disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Review article: anti-adhesion therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Review article: defining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Histologic markers of inflammation in patients with ulcerative colitis in clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365521.2014.977943

10.3109/00365521.2014.977943

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference